

Applicants: Cristoph Hock et al.  
Serial No.: 10/554,314  
Filed: April 19, 2006  
Page 4

#### **REMARKS**

Claims 1, 4-7 and 11-18 are pending in the subject application. Claims 11-17 are withdrawn from consideration as being drawn to non-elected inventions. Applicants have hereinabove amended claim 1 and canceled claims 3-7 and 18 without disclaimer or prejudice to applicants' right to pursue the subject matter of these claims in the future. Support for the amendment to claim 1 may be found in the specification, *inter alia*, at page 2, lines 6-13 as well as in the Examples, for example at page 13, lines 1-19; page 15, last paragraph, 1<sup>st</sup> sentences; page 19, middle paragraph . 1<sup>st</sup> sentence and original claim 4. Applicants have added new claim 19. Support for new claim 19 may be found in the specification, *inter alia*, at page 3, lines 8-11 and in the Examples, for example at page 11, 1<sup>st</sup> sentence. Upon entry of this Amendment, claims 1 and 19 will be pending and under examination.

#### **Information Disclosure Statement**

Applicants acknowledge that the Examiner, on page 3 of the Final Office Action, has considered all the references listed in the Information Disclosure Statement filed May 6, 2008 except for EP1172378 since it was cited by the Examiner on form PTO 892 mailed May 3, 2007.

#### **Withdrawn Rejections**

Applicants note that the Examiner has withdrawn, on page 3 of the December 23, 2008 Final Office Action, the rejection of claims 1, 3-7 and 18 under 35 U.S.C. §112, second paragraph, as being indefinite.

#### **Rejection Under 35 U.S.C. §112**

The Examiner rejected claim 1, 4-7 and 18 under 35 U.S.C. §112, first paragraph, for allegedly failing to satisfy the enablement requirement.

Specifically, in section 7 at page 4 of the Final Office Action, the Examiner states that "Claims 1, 4-7 and 18 stand rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for detecting an increased level of immunostaining on brain sections of APP<sup>SW</sup>xPS1<sup>M146L</sup> transgenic mice or increased levels of antibodies against  $\beta$ -amyloid in serum and CSF samples of Alzheimer disease (AD) patients who are immunized with A $\beta$  peptides,

AN1792(QS-21), and detecting a positive correlation between the increased immunostaining and improvement of immunization treatment in AD patients, does not reasonably provide enablement for a method of monitoring an immunotherapy in a subject suffering from Alzheimer's disease by contacting all types of test samples with all forms of amyloid plaque (including all fragments, derivatives or mutants) in all types of tissue sections and comparing the level of immunoreactivity to an undefined reference value of AD as broadly claimed."

In response, applicants respectfully traverse the Examiner's ground of rejection. Nevertheless, without conceding the correctness of the Examiner's rejection, applicants note that claim 1 has been amended hereinabove to recite that the immunoreactivity is detected on brain sections of APP<sup>SW</sup>xPS1<sup>M146L</sup> transgenic mice in serum or CSF samples of Alzheimer's disease patients who are immunized with pre-aggregated A $\beta$ 1-42.

In view of this amendment, applicants maintain that the Examiner's ground of rejection has been rendered moot.

In view of the preceding remarks and the amendments to the claims, applicants maintain that claim 1 as amended and new claim 19 which depends therefrom satisfy the enablement requirement of 35 U.S.C. § 112, first paragraph. Accordingly, applicants respectfully request that the Examiner reconsider and withdraw this ground of rejection under 35 U.S.C. §112, first paragraph.

#### **Rejections Under 35 U.S.C. §103**

In section 8 at page 7 of the Final Office Action, the Examiner rejected claims 1, 4-7 and 18 under 35 U.S.C. §103 as allegedly not patentable over Dodel et al. (EP 1 172 378, published on January 16, 2002 as cited in the previous Office Action, hereinafter "Dodel") in view of Schenk et al. (Nature 400 (1999), 173-1779, hereinafter "Schenk").

In response, applicants respectfully traverse the Examiner's ground of rejection. Nevertheless, without conceding the correctness of the Examiner's rejection, applicants note that claim 1 has been amended hereinabove to recite that the immunoreactivity is detected on brain sections of APP<sup>SW</sup>xPS1<sup>M146L</sup> transgenic mice in serum or CSF samples of Alzheimer's disease patients who are immunized with pre-aggregated A $\beta$ 1-42.

In this context, the Examiner is reminded that the same standard has to be applied for the assessment of the subject application and the cited prior art. Thus, when stating that the present application allegedly does not reasonably provide enablement for immunostaining on brain sections other than the mutant human APP and human Presenilin1 double-transgenic mice the same must apply to the prior art. Thus, the Schenk reference merely describing the mutant human APP (PDAPP) transgenic mice does not provide the person skilled in the art with enabling teaching for detecting an increased level of immunostaining on brain sections of the APP<sup>SW</sup>xPS1<sup>M146L</sup> double-transgenic mice, let alone a reasonable expectation that those brain sections of a non-human animal could be used in a method of monitoring and prognosticating the clinical outcome of an immunotherapy in a human subject suffering from Alzheimer's disease and being immunized against pre-aggregated A $\beta$ 1-42.

This is all the more true in view of the fact that in accordance with the method of the present invention **human** antibody-containing serum and CSF sample are used to screen against an **animal**, i.e. mouse brain section and thus an immunoreactivity of components from different species.

Furthermore, the Examiner neglects the fact that besides Dodel fails to teach contacting serum or CSF with a brain section containing amyloid-plaques, wherein said brain section is derived from transgenic mice, in Dodel the level of anti-A $\beta$  antibody is detected in samples from patients who have been passively immunized with human IgG immunoglobulins or anti-A $\beta$  antibodies from human IgG rather than

immunized with A $\beta$ 1-42 as recited in the claim.

Furthermore, Dodel teaches "[t]he generation of naturally occurring A $\beta$ -antibodies and subsequent A $\beta$  / antibody complex formation, maybe involved in a normal clearance of A $\beta$  peptide(s)"; see Dodel in column 3, section [0019], lines 42-45.

However, it is clear that the A $\beta$  / antibody complex is formed with soluble A $\beta$ . Thus, it would make no sense to screen for those antibodies which are supposed to form a complex with A $\beta$  in human fluid in order to prevent A $\beta$  deposition with brain tissue sections containing amyloid-plaques. This is all the more true in view of the fact that the epitopes recognized by the anti-A $\beta$  antibodies taught in Dodel would be expected by the person skilled in the art to not match the epitopes that are accessible on the  $\beta$ -amyloid plaques present on the brain section.

Furthermore, contrary to the Examiner's assertion with reference to KSR International Co. v. Teleflex Inc. 82 USPQ2d 1385 (2007), plaque-containing brain sections of transgenic mice were not known to be suitable for the detection of protective human auto-antibodies against pre-aggregated A $\beta$ 1-42. The corresponding statement of the Examiner at page 9 of the Office Action that "[t]he detection of reduced amyloid plaques in immunized PDAPP mice as compared to non-immunized mice indicates that the antibodies generated from Abeta immunization can recognize amyloid plaques and thus there is a higher level staining in non-immunized mice" is based on hindsight assertion and not supported by Schenk. In particular, the Examiner asserts

"Although Schenk does not directly use brain sections of non-immunized PDAPP mice to detect the levels of anti-Abeta antibodies in immunized mice, **it is expected to detect higher levels of amyloid-plaques on brain sections derived from non-immunized transgenic animals** and use as an indicator because the levels of anti-Abeta antibodies from patients or animals with Abeta immunization are

increased in serum and CSF, and **can recognize the epitopes of A $\beta$  (immunogen) on the brain sections of non-immunized transgenic PDAPP animals** (amyloid-plaque containing tissue sections). Thus, the increased immunoreactivity as compared to prior to immunotherapy on brain sections containing human amyloid-plaques (PDAPP) is expected when contacted with the serum or CSF derived from animals or patients immunized with Abeta and thus to monitor the efficacy of immunotherapy. Accordingly, the claimed method as recited in instant claims are obvious over the applied references **because animals or patients immunized with A $\beta$  generate anti-A $\beta$  antibodies against A $\beta$  plaques** and show reduced A $\beta$  burden. Thus, a skilled artisan would have expected success in monitoring an immunotherapy in a subject suffering from AD by using brain sections of transgenic animals containing amyloid plaques as a tool to detect the anti-Abeta level after immunization because detection of higher levels of amyloid-plaques on brain sections of PDAPP mice is expected and the increased level of anti-Abeta antibodies in AD immunized with Abeta has been shown to reduce Abeta burden as taught by Schenk Dodel [sic], which is as an indicator of improvement of the immunotherapy in AD". See Office Action at pages 9 and 10 (emphasis added).

The assertion by the Examiner that "animals or patients immunized with A $\beta$  generate anti-A $\beta$  antibodies against A $\beta$  plaques" is neither taught nor suggested in Schenk. Rather, Schenk states

"Although it remains unproven, it is not unreasonable to expect that a similar reduction of neuropathology in AD patients would be of clinical benefit. Although our understanding of the precise aspects of the immune response that result in reduced pathology is incomplete, we have shown that A $\beta_{42}$  immunization results in the generation of anti-A $\beta$  antibodies and that A $\beta$ -immunoreactive monocytic/microglial cells appear in the regions of remaining plaques. Thus, one possible mechanism of action is that anti-A $\beta$  antibodies facilitate clearance of amyloid- $\beta$  either before deposition, or after plaque formation, by triggering monocytic/microglial cells to clear amyloid- $\beta$  using signals mediated by Fc receptors". See Schenk at page 177, left column, third last full paragraph (emphasis added).

Thus, Schenk concludes that the anti-A $\beta$  antibodies bind amyloid- $\beta$  before deposition, i.e. plaque formation. Alternatively, Schenk

suggests that the anti-A $\beta$  antibodies trigger monocytic/microglial cells to clear amyloid- $\beta$ . There is no mentioning whatsoever that the anti-A $\beta$  antibodies can recognize A $\beta$  plaques on brain tissue, let alone that this could be an indicator for the success of immunotherapy.

Indeed, Schenk is acknowledged in Dodel in that way:

Schenk and coworkers (Schenk et al, Nature 400:173, 1999) **investigated the plaque burden** in the PDAPP-mice following an immunization treatment. PDAPP-mice were immunised with pre-aggregated A $\beta$  20 for different time periods using Freud's adjuvans. **Plaque deposition in these mice decreased significantly** following the immunization treatment". See Dodel at 2, column 2, section [0008] (emphasis added).

Even Dodel being aware of the teaching of Schenk and as an inventor having skill above the average person skilled in the art has not envisaged that amyloid-plaque containing tissue sections of, for example, the transgenic PDAPP animals may be useful in monitoring an immunotherapy in a subject suffering from AD.

Rather, as stated by Dodel "[t]he goal is to **decrease  $\beta$ -amyloid concentration in the CSF and by that decrease the plaque burden** in Alzheimer's disease and alleviate the neuropsychiatric and neuropsychological defects in Alzheimer's disease. See Dodel in Example 1 at page 4, right column, lines 51-55 (emphasis added). Consequently, in Example 2 of Dodel, which is the only Example describing the effect of IgG immunoglobulin administration  $\beta$ -amyloid is measured in order to assess the efficacy of the treatment.

Thus, as acknowledged by the Examiner at page 11 and 12 of the Office Action assessing and determining the clinical outcome of immunotherapy of A $\beta$ -immunization is taught by both Dodel and Schenk to be done by quantifying the amyloid- $\beta$  burden and NOT by quantifying immunoreactivity on amyloid-plaque containing tissue sections.

Hence, since Dodel as well as Schenk propose that the anti-A $\beta$

antibodies exert the effect of lowering plaque burden by facilitating clearance and thus binding of A $\beta$  in serum and CSF before plaque deposition, the skilled person would not have expected that the epitopes of soluble A $\beta$  recognized by the anti-A $\beta$  antibodies do not match the epitopes that are accessible on the  $\beta$ -amyloid plaques present on the brain section. Thus, it would make no sense to screen for those antibodies which are supposed to form a complex with soluble A $\beta$  in human fluid in order to prevent A $\beta$  deposition with brain tissue sections containing amyloid-plaques.

In summary, there is no indication in Schenk whatsoever that the antibodies generated from A $\beta$  immunization can recognize amyloid plaques. Accordingly, it can also not be expected to detect higher levels of anti-A $\beta$  antibodies on brain sections derived from the non-immunized transgenic animals, let alone that this would be an indicator for a successful therapeutic outcome. There is no teaching in Schenk that the anti-A $\beta$  antibodies shown to be increased in serum and CSF can recognize the epitopes of A $\beta$  on the brain sections of non-immunized transgenic PDAPP animals since, as mentioned, Schenk as well as Dodel teach and suggest that the generated anti-A $\beta$  antibodies prevent plaque formation beforehand.

Furthermore, contrary to the Examiner's assertion at page 11 and 12 of the Office Action Schenk does NOT teach a positive correlation of the level of anti-A $\beta$  antibodies in serum and CSF after treatment or immunization with A $\beta$ . Schenk states:

"We found that eight of nine PDAPP mice immunized with A $\beta$ 42 developed and maintained serum antibody titres against A $\beta$ 42 of greater than 1:10,000. The ninth mouse had a lower titre, of approximately 1:1,000.

...

Immunization with A $\beta$ 42 resulted in almost complete prevention of amyloid- $\beta$  deposition (Figs 1, 2). Seven of nine mice immunized with A $\beta$ 42, including the mouse with

the lowest anti-A $\beta$  titre, had no detectable amyloid- $\beta$  deposits in their brains. One mouse from this treatment group had a single isolated plaque in the six brain sections examined, whereas a second animal had a greatly reduced amyloid- $\beta$  burden". See Schenk at page 174, left column, third last full sentence and right column, lines 4-10 (emphasis added).

Hence, a mouse having an anti-A $\beta$  antibody titre of more a magnitude less than the mean performed as good as the mice having high titres and even better than two of those. Thus, according to the observation by Schenk the level of anti-A $\beta$  antibodies does not indicate the outcome of neuropathology in terms of A $\beta$  burden and amount of plaque deposits in the brain. Hence, for the second series of experiments described at page 176 Schenk confined its analysis to the examination of A $\beta$  burden similarly as Dodel in its Example 2.

However, as discussed in the present application and meanwhile acknowledged in the art determining the level of A $\beta$  does also not allow any conclusion as to the significance of this observation for the clinical outcome of the therapy of patients suffering from Alzheimer's disease.

Indeed, this is one significant shortcoming of the method of monitoring immunotherapy taught in Dodel and Schenk because of which applicants' contribution to the art has been acknowledged in the field of Alzheimer's disease to represent "an important step forward to ultimately treat this intractable disease"; see Sambamurti et al. at page 176, right column, last sentence. Certainly, the skilled person could not have expected that immunized patients with unchanged plasma and CSF level of A $\beta$ , when scored positive in the TAPIR assay of the claimed invention clinically improved and even performed better than patients having high ELISA titers; see the specification at page 19, the bridging paragraph to page 20 and the last paragraph at that page.

For the reasons stated above, applicants maintain that Dodel et al. in view of Schenk et al. 1999 or Schenk (US'523) do not render obvious applicants' claimed invention.



Applicants: Cristoph Hock et al.  
Serial No.: 10/554,314  
Filed: April 19, 2006  
Page 12


In view of these remarks, applicants maintain that claim 1 as amended and the claims which depend therefrom, satisfy the requirements of 35 U.S.C. §103. Accordingly, applicants respectfully request the Examiner reconsider and withdraw this ground of rejection.

**Summary**


If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee is deemed necessary in connection with the filing of this Amendment. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White  
Registration No. 28,678  
Attorney for Applicants  
Cooper & Dunham, LLP  
30 Rockefeller Plaza, 20<sup>th</sup> Floor  
New York, New York 10112  
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:	
<b>Mail Stop AF</b> Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	
	2/23/09
John P. White Reg. No. 28,678	Date